^
Association details:
| Biomarker: | EGFR-RAD51 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature
Published date:
01/14/2022
Excerpt:
Herein, we report the case of two young non smoker females with metastatic NSCLC harboring EGFR-RAD51 gene fusion...first-generation EGFR-TKI erlotinib...was administered leading to a PR on all tumor sites...The third generation TKI osimertinib (80 mg daily) was then administered, with further tumor response at the subsequent restaging imaging.
DOI:
https://dx.doi.org/10.21037/tlcr-21-888
